What Analysts Recommend for Kimberly-Clark
Analysts remain neutral
Kimberly-Clark’s (KMB) 2H17 results are expected to benefit from new and updated products. Moreover, the company’s focus on reducing costs through the tight control of overhead expenses and a lower effective tax rate is projected to drive its bottom-line growth.
However, analysts remain on the sidelines as continued softness in demand, higher competition, lower pricing, and inflation in commodity prices are anticipated to hurt its financials. 14 out of 15 analysts covering the stock have rated it a “hold,” and only one analyst has provided a “buy” rating. Meanwhile, analysts have a target price of $128.07 per share on KMB stock, implying a potential upside of 8.7% when compared to the closing price of $117.84 on October 11.
Interested in CHD? Don't miss the next report.
Receive e-mail alerts for new research on CHD
In comparison, analysts also maintain a neutral stance on other consumer product companies including Colgate-Palmolive (CL), Procter & Gamble (PG), and Clorox (CLX). Decelerating category growth, increased input costs, and rising competition is expected to restrict the upside of consumer product companies.
As of October 11, 2017, Kimberly-Clark stock was trading at a forward PE ratio of 18.6x, which is below the peer group average of 23.4x. On the same day, Colgate-Palmolive, Church & Dwight (CHD), Clorox and Procter & Gamble were trading at a forward PE multiple of 24.9x, 23.7x, 23.2x, and 22.0x, respectively.
Despite the company’s low valuation in comparison to its peers, Kimberly-Clark is failing to attract investors owing to its tepid growth rate projection.